In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.  

A recent gene therapy death shines a light on AAV safety

This technology brings both benefits and drawbacks for the field, which is also testing alternatives.